The Second Coming of Daclizumab
Daclizumab (Zinbryta) has recently been approved by US and European regulators for the treatment of relapsing multiple sclerosis. In fact, it’s not the first foray onto the drug market for the CD25 antibody – in 1997, the drug was approved to treat transplant rejection, only to be withdrawn 12 years later for commercial reasons.
Thomas Waldmann |
Here, Thomas Waldmann, Co-Chief of the Lymphoid Malignancies Branch at the National Cancer Institute, shares a translational odyssey – from chance discovery to welcome return.
Read the full article now
Log in or register to read this article in full and gain access to The Translational Scientist’s entire content archive. It’s FREE!
Login
Or register now - it’s free!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
